Cebranopadol

What is Cebranopadol?#

Cebranopadol (GRT-6005/TRN-228) is a first-in-class oral analgesic that targets both the nociceptin/orphanin FQ peptide (NOP) receptor and classical opioid receptors (mu, delta, and kappa). Originally discovered by Grunenthal GmbH in Germany, cebranopadol is now being developed by Tris Pharma for the treatment of moderate-to-severe acute and chronic pain.

Unlike traditional opioid analgesics that act primarily through mu-opioid receptors, cebranopadol's dual NOP/opioid mechanism represents a fundamentally different pharmacological approach to pain management. The NOP receptor component provides anti-hyperalgesic effects while counteracting several of the problematic side effects associated with pure mu-opioid agonists, including respiratory depression and abuse potential.

Cebranopadol has been evaluated in more than 33 clinical trials encompassing over 2,300 participants. Two pivotal Phase 3 trials (ALLEVIATE-1 and ALLEVIATE-2) for acute pain have reported positive results, and the compound holds FDA Fast Track designation for chronic low back pain.

Mechanism of Action#

Cebranopadol exerts its analgesic effects through a dual receptor mechanism:

• NOP receptor agonism: Cebranopadol binds with sub-nanomolar affinity to the nociceptin/orphanin FQ peptide receptor (NOP, also called ORL-1). NOP receptor activation modulates pain signaling through the endogenous nociceptin system and contributes to anti-hyperalgesic effects, particularly in chronic and neuropathic pain states
• Mu-opioid receptor (MOP) agonism: Full agonist activity at MOP receptors provides conventional opioid-type analgesia
• Delta and kappa opioid receptors: Approximately 20-fold lower affinity for DOP and KOP receptors compared to NOP and MOP, contributing additional analgesic modulation

The critical mechanistic advantage is that NOP receptor activation ameliorates several MOP-mediated side effects. Preclinical studies have demonstrated that cebranopadol's NOP activity reduces respiratory depression risk and contributes to lower abuse potential compared to pure mu-opioid agonists. This dual mechanism produces robust analgesia with a side effect profile that is improved relative to traditional opioids.

Clinical Development#

Cebranopadol has progressed through a comprehensive clinical program:

• ALLEVIATE-1 (Phase 3): Randomized, double-blind, placebo-controlled trial in patients following abdominoplasty. Cebranopadol 400 mcg once daily for two days demonstrated statistically significant pain reduction vs placebo (LS Mean difference 59.2; p<0.001), with significantly fewer rescue medication doses required
• ALLEVIATE-2 (Phase 3): Randomized, double-blind, placebo- and active-controlled trial in 240 patients following bunionectomy. Cebranopadol 400 mcg once daily showed significant pain reduction vs placebo (LS Mean difference 56.1; p<0.001), with efficacy comparable to or exceeding oxycodone IR 10 mg four times daily
• Phase 2 Chronic LBP: 14-week trial across 79 sites in 11 countries. All cebranopadol doses (200, 400, 600 mcg) showed significant improvements over placebo in chronic low back pain
• Abuse Liability Study: Cebranopadol 200-400 mcg did not differentiate from placebo on drug-liking measures; lower abuse potential confirmed vs hydromorphone
• FDA Fast Track Designation: Granted for chronic low back pain

Tris Pharma plans to submit a New Drug Application (NDA) to the FDA in 2025 based on the completed acute pain program, with chronic pain studies planned to begin subsequently.

Important Considerations#

Cebranopadol is an investigational medication not yet approved by any regulatory authority. Key considerations include:

• Despite lower abuse potential than pure opioids, cebranopadol still acts at opioid receptors and is not devoid of opioid-type effects at higher doses
• Common adverse events include nausea, dizziness, somnolence, and constipation, consistent with its opioid receptor activity
• The long terminal half-life (62-96 hours) means effects and side effects may persist; dose adjustments require patience
• Clinical trial data for chronic pain indications are limited to Phase 2; Phase 3 chronic pain trials have not yet been conducted
• Higher doses during titration were associated with increased treatment discontinuation due to adverse events

Key Research Findings#

Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain, published in Pain (Christoph T, Eerdekens MH, Kok M, et al., 2017; PMID: 28644196):

• All cebranopadol doses (200, 400, 600 mcg) showed statistically significant improvements over placebo
• Responder analysis confirmed clinically relevant pain relief at both 30% and 50% reduction thresholds
• Beneficial effects on sleep quality and physical functionality

Assessment of the Abuse Potential of Cebranopadol, published in Journal of Clinical Psychopharmacology (Goehler K, et al., 2019; PMID: 30531478):

• At clinical doses (200-400 mcg), cebranopadol did not differentiate from placebo on drug-liking measures
• Lower abuse potential confirmed compared to hydromorphone IR

Related Reading#

• Cebranopadol research studies and evidence
• Cebranopadol dosing protocols
• Cebranopadol side effects profile
• Ziconotide research guide
• Dermorphin research guide